Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic
  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Aptose Announces Results from Special Meeting of Shareholders

SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), announced the voting results from its special meeting of shareholders held today, September 5, 2024 (the “Meeting”).

A total of 6,052,460 common shares of the Company (the "Shares"), representing 33.42% of the issued and outstanding Shares were voted at the Meeting.

The proposals put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated July 11, 2024 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below:

  1. Proposal No. 1 – passing a resolution, the full text of which is set forth in the Proxy Statement, approving the issuance of common shares of the Corporation underlying certain warrants pursuant to Nasdaq Listing Rules; and
  2. Proposal No. 2 – passing a resolution, the full text of which is set forth in the Proxy Statement, approving one or more adjournments of the Meeting, if necessary or appropriate, if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes at the time of the Meeting to approve Proposal No. 1.

Please refer to the Company’s Proxy Statement available on SEDAR+ at www.sedarplus.ca or EDGAR https://www.sec.gov/edgar.shtml for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+ and EDGAR.

The detailed results of the vote at the Meeting are set out below:

 
APTOSE BIOSCIENCES INC.
ADJOURNED SPECIAL MEETING OF SHAREHOLDERS HELD ON SEPTEMBER 5, 2024

REPORT ON PROXIES
 
 

MOTIONS
NUMBER OF SHARES PERCENTAGE OF VOTES CAST
FOR AGAINST
WITHHELD/
ABSTAIN

RESTRICTED
NON
VOTE

FOR
AGAINST
WITHHELD/
ABSTAIN
Approval of Nasdaq 20%
Issuance Proposal

3,969,105*

267,013

16,342

1,800,000

093.34%6.28%
0.38%
Multiple Adjournments
5,873,779

138,958

39,722

 197.05%
2.30%
0.66%


*    Excluding 1,800,000 shares held by Insiders  
   
TOTAL SHAREHOLDERS VOTED BY PROXY: 47 
   
TOTAL SHARES ISSUED & OUTSTANDING: 18,109,393 
   
TOTAL SHARES VOTED: 6,052,460 
   
TOTAL % OF SHARES VOTED: 33.42%  
   

About Aptose

Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.  

For further information, please contact: 

Aptose Biosciences Inc.                                                                   
Susan Pietropaolo                                                                              
Corporate Communications & Investor Relations                               
201-923-2049                                                                                     
spietropaolo@aptose.com


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.